# Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL

> **NCT07476027** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 10 (estimated)

## Conditions studied

- T Lymphoblastic Lymphoma
- T Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** CD7 CAR-T cell intravenous infusion

## Key facts

- **NCT ID:** NCT07476027
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-15
- **Primary completion:** 2029-04-01
- **Final completion:** 2029-06-27
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476027, "Efficacy and Safety of CD7 CAR-T in Newly Diagnosed High-Risk T-LBL/ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07476027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*